Cargando…

Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy

Immunosuppressive therapy is mandatory for primary membranous nephropathy with persistent nephrotic proteinuria or anti-phospholipase A2 receptor antibodies, reduced kidney function, or another risk factor for progression. Rituximab has demonstrated efficacy for proteinuria remission compared with r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rojas-Rivera, Jorge, Fervenza, Fernando C., Ortiz, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844164/ https://www.ncbi.nlm.nih.gov/pubmed/34932208 http://dx.doi.org/10.1007/s40265-021-01656-1

Ejemplares similares

Novel Treatments Paradigms: Membranous Nephropathy
por: Rojas-Rivera, Jorge E., et al.
Publicado: (2023)

Future landscape for the management of membranous nephropathy
por: Caravaca-Fontán, Fernando, et al.
Publicado: (2023)

Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy
por: Zand, Ladan, et al.
Publicado: (2023)

“Precision” Medicine in Membranous Nephropathy: Serology-Guided Therapy
por: Glassock, Richard J., et al.
Publicado: (2023)

Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy
por: Cheungpasitporn, Wisit, et al.
Publicado: (2016)

Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal
por: Rojas-Rivera, Jorge Enrique, et al.
Publicado: (2019)

Recent Progress in Deciphering the Etiopathogenesis of Primary Membranous Nephropathy
por: Kronbichler, Andreas, et al.
Publicado: (2017)

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
por: Fervenza, Fernando C, et al.
Publicado: (2008)

Heterogeneity of Target Antigens in Sarcoidosis-Associated Membranous Nephropathy
por: Zubidat, Dalia, et al.
Publicado: (2023)

A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus–Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study
por: Rojas-Rivera, Jorge, et al.
Publicado: (2015)

Proteomic Analysis of Complement Proteins in Membranous Nephropathy
por: Ravindran, Aishwarya, et al.
Publicado: (2020)

Mechanisms of Primary Membranous Nephropathy
por: Gu, Yan, et al.
Publicado: (2021)

Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy
por: Wang, Yan-Ni, et al.
Publicado: (2022)

Profile and primary treatment outcomes in membranous nephropathy
por: Hemanth Kumar, M.K., et al.
Publicado: (2022)

The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years
por: Martínez-Castelao, Alberto, et al.
Publicado: (2015)

Present and Future of IgA Nephropathy and Membranous Nephropathy Immune Monitoring: Insights from Molecular Studies
por: Zanoni, Francesca, et al.
Publicado: (2023)

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2022)

Mechanistic Insight and Management of Diabetic Nephropathy: Recent Progress and Future Perspective
por: Xue, Rui, et al.
Publicado: (2017)

Biological Insight and Recent Advancement in the Treatment of Neuroblastoma
por: Rivera, Zoriamin, et al.
Publicado: (2023)

Editorial: Primary membranous nephropathy
por: Infantino, Maria
Publicado: (2022)

Clinical implications of pathological features of primary membranous nephropathy
por: Zhang, Xiao-dan, et al.
Publicado: (2018)

Clinical Phenotypes and Predictors of Remission in Primary Membranous Nephropathy
por: Jurubiță, Roxana, et al.
Publicado: (2021)

Clinical covariates influencing clinical outcomes in primary membranous nephropathy
por: Westermann, Lukas, et al.
Publicado: (2023)

An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression
por: Zand, Ladan, et al.
Publicado: (2019)

Noninvasive Urinary Monitoring of Progression in IgA Nephropathy
por: Yang, Joshua Y. C., et al.
Publicado: (2019)

How to Choose the Right Treatment for Membranous Nephropathy
por: Peritore, Luigi, et al.
Publicado: (2023)

Membranous nephropathy
por: Dantas, Márcio, et al.
Publicado: (2023)

Immunology of membranous nephropathy
por: Akiyama, Shin'ichi, et al.
Publicado: (2019)

Advances in Membranous Nephropathy
por: Ronco, Pierre, et al.
Publicado: (2021)

Rituximab in Membranous Nephropathy
por: Gauckler, Philipp, et al.
Publicado: (2021)

Perspectives in membranous nephropathy
por: Tomas, Nicola M., et al.
Publicado: (2021)

Correction to: Clinical covariates influencing clinical outcomes in primary membranous nephropathy
por: Westermann, Lukas, et al.
Publicado: (2023)

Clinical Outcomes of Patients With Primary Membranous Nephropathy and Subnephrotic Proteinuria
por: He, Peng, et al.
Publicado: (2021)

Clinical and Histopathologic Characteristics of Pediatric Patients With Primary Membranous Nephropathy
por: Kouri, Anne M., et al.
Publicado: (2023)

Choroidal Neovascularization in Primary Membranous Nephropathy
por: Gambato, Tommaso, et al.
Publicado: (2020)

Hydrogen Sulfide: Recent Progression and Perspectives for the Treatment of Diabetic Nephropathy
por: Sun, Hai-Jian, et al.
Publicado: (2019)

Membranous nephropathy: Treatment outline and risk stratification
por: Arabi, Ziad
Publicado: (2012)

IgA Nephropathy: Current Treatment and New Insights
por: Petrou, Dimitra, et al.
Publicado: (2023)

A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy
por: Hladunewich, Michelle A., et al.
Publicado: (2014)

Recent advances in managing and understanding diabetic nephropathy
por: Tang, Sydney C.W., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hfj57vvisk9r02554tl5amrs7k